Seroprevalence of human enterovirus A71 in Guangzhou, China, 2019–2021

被引:2
|
作者
Lian Huimin [1 ]
Jiang Huimin [1 ]
Yi Lina [5 ]
Sun Jing [8 ]
Xie Huaping [11 ]
Qiu Ming [5 ]
Sun Limei [13 ]
Lin Huifang [5 ]
Yang Mingda [5 ]
Qu Lin [5 ]
Yang Haiyi [5 ]
Lu Jing [1 ]
Zeng Hanri [13 ]
机构
[1] Guangzhou Center for Disease Control and Prevention
[2] Guangzhou 510440
[3] Guangdong Workstation for Emerging Infectious Disease Control and Prevention
[4] Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response
[5] School of Public Health
[6] Southern Medical University  3. Guangzhou 510515  4. China
[7] Guangdong Provincial Institution of Public Health
[8] Guangdong Provincial Center for Disease Control and Prevention  7. Guangzhou 511430
[9] Health Commission of Heping District
[10] Shenyang City  10. Liaoning 110003
关键词
Enterovirus A71; Vaccine; Seroepidemiology;
D O I
暂无
中图分类号
R725.1 [小儿传染病];
学科分类号
100202 ;
摘要
Enterovirus A71 (EV-A71) is a significant hand-foot-mouth disease (HFMD) etiology. The inactivated EV-A71 vaccines were approved in China in 2016. However, the seroprevalence of EV-A71 after the vaccine application and its potential association with the EV-A71 epidemic in the population are rarely studied. In this study, we analyzed the incidence of EV-A71 infection and seroepidemiology in Guangzhou City, China. From 2019 to 2021, 167,920 clinically confirmed HFMD cases were reported in Guangzhou. In 6,868 enterovirus-positive samples, Coxsackievirus A6 and Coxsackievirus A16 were dominant genotypes, and only 3 EV-A71-positive samples were detected, highlighting the deficient epidemic activity of EV-A71. Microneutralization assay was performed on 1,000 representative serum samples. Notably, the seroprevalence and geometric mean titer (GMT) decreased significantly in 2020, and that in the < 3-year age group were increased and even higher than that in 3–5-year age group in 2019 and 2021, which was contrary to our previous surveillance result and other studies in Guangzhou. Furthermore, a moderate decline of GMT level was observed following the vaccination, but the seropositive serums were still detected for 49 months after second immunization, suggesting the long-term persistence of the immunity. Our seroepidemiology study revealed relatively higher neutralizing antibody activity in the susceptible population after the EV-A71 vaccine was adopted in 2016 in Guangzhou. It may be one of the reasons for the lower epidemic activity of EV-A71 in Guangzhou from 2019 to 2021.
引用
收藏
相关论文
共 50 条
  • [41] Identification of fukinolic acid from Cimicifuga heracleifolia and its derivatives as novel antiviral compounds against enterovirus A71 infection
    Ma, Yipeng
    Cong, Wenjuan
    Huang, Hao
    Sun, Liang
    Mai, Anh Hung
    Boonen, Kurt
    Maryam, Wahedi
    De Borggraeve, Wim
    Luo, Guoan
    Liu, Qingfei
    Schoofs, Liliane
    Van Kuppeveld, Frank
    Neyts, Johan
    Mirabelli, Carmen
    Luyten, Walter
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 53 (02) : 128 - 136
  • [42] Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology
    Yang, Ya-Ting
    Chow, Yen-Hung
    Hsiao, Kuang-Nan
    Hu, Kai-Chieh
    Chiang, Jen-Ron
    Wu, Suh-Chin
    Chong, Pele
    Liu, Chia-Chyi
    ANTIVIRAL RESEARCH, 2016, 132 : 225 - 232
  • [43] Therapeutic and prevention strategies against human enterovirus 71 infection
    Chee Choy Kok
    World Journal of Virology, 2015, (02) : 78 - 95
  • [44] Molecular characteristics of the VP1 region of enterovirus 71 strains in China
    Sun, Haiyan
    Gao, Min
    Cui, Dawei
    GUT PATHOGENS, 2020, 12 (01)
  • [45] A Polysaccharide Purified From Ganoderma lucidum Acts as a Potent Mucosal Adjuvant That Promotes Protective Immunity Against the Lethal Challenge With Enterovirus A71
    Lin, Yu-Li
    Shih, Chiaho
    Cheng, Pei-Yun
    Chin, Chiao-Li
    Liou, An-Ting
    Lee, Po-Yi
    Chiang, Bor-Luen
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [46] A 5-year molecular epidemiology survey of human enterovirus 71 before vaccine application in Yunnan Province, China
    Liu, Hong-Bo
    Yu, Liang
    Zhang, Jie
    Huang, Xiao-Qin
    Yang, Zhao-Qing
    Liao, Guo-Yang
    Sun, Hao
    Ma, Shao-Hui
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (08) : 1085 - 1092
  • [47] Seroprevalence of Diphtheria and Tetanus Immunoglobulin G among the General Health Population in Guangzhou, China
    He, Qing
    Wu, Yejian
    Hou, Shuiping
    Luo, Lei
    Zhang, Zhoubin
    VACCINES, 2024, 12 (04)
  • [48] Substitution of Coxsackievirus A16 VP1 BC and EF Loop Altered the Protective Immune Responses in Chimera Enterovirus A71
    Tan, Xiu Hui
    Chong, Wei Lim
    Lee, Vannajan Sanghiran
    Abdullah, Syahril
    Jasni, Kartini
    Suarni, Saiful Qushairi
    Perera, David
    Sam, I-Ching
    Chan, Yoke Fun
    VACCINES, 2023, 11 (08)
  • [49] Novel Anti-Enterovirus A71 Compounds Discovered by Repositioning Antivirals from the Open-Source MMV Pandemic Response Box
    Lochaiyakun, Nattinee
    Srimanote, Potjanee
    Khantisitthiporn, Onruedee
    Thanongsaksrikul, Jeeraphong
    PHARMACEUTICALS, 2024, 17 (06)
  • [50] Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017-2022: a descriptive study
    Duan, Xiaoxia
    Zhang, Chaoyong
    Wang, Xiao
    Ren, Xueling
    Peng, Hongxia
    Tang, Xueqin
    Zhang, Liangzhi
    Chen, Zhenhua
    Ye, Yan
    Zheng, Mengmou
    Zhong, Wanzhen
    Chen, Xiyue
    Zeng, Yilan
    Yuan, Ping
    Long, Lu
    EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 2510 - 2519